26-02-2026, 19:05

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics

Notified -
Globe Newswire26-02-2026, 19:05
4-11-2025, 20:00

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

Notified -
Globe Newswire4-11-2025, 20:00
30-10-2025, 13:40

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases

Notified -
Globe Newswire30-10-2025, 13:40